- Home
- DORM vs IONS Comparison
DORM vs IONS Comparison
Compare DORM & IONS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DORM
- IONS
- Stock Information
- Founded
- DORM 1978
- IONS 1989
- Country
- DORM United States
- IONS United States
- Employees
- DORM N/A
- IONS N/A
- Industry
- DORM Auto Parts:O.E.M.
- IONS Biotechnology: Pharmaceutical Preparations
- Sector
- DORM Consumer Discretionary
- IONS Health Care
- Exchange
- DORM Nasdaq
- IONS Nasdaq
- Market Cap
- DORM 3.9B
- IONS 4.6B
- IPO Year
- DORM 1991
- IONS 1991
- Fundamental
- Price
- DORM $111.18
- IONS $28.40
- Analyst Decision
- DORM Strong Buy
- IONS Buy
- Analyst Count
- DORM 1
- IONS 18
- Target Price
- DORM $153.00
- IONS $57.00
- AVG Volume (30 Days)
- DORM 329.1K
- IONS 2.0M
- Earning Date
- DORM 05-05-2025
- IONS 04-30-2025
- Dividend Yield
- DORM N/A
- IONS N/A
- EPS Growth
- DORM 49.76
- IONS N/A
- EPS
- DORM 6.14
- IONS N/A
- Revenue
- DORM $2,009,197,000.00
- IONS $705,138,000.00
- Revenue This Year
- DORM $6.36
- IONS N/A
- Revenue Next Year
- DORM $4.91
- IONS $25.80
- P/E Ratio
- DORM $18.11
- IONS N/A
- Revenue Growth
- DORM 4.12
- IONS N/A
- 52 Week Low
- DORM $86.61
- IONS $23.95
- 52 Week High
- DORM $146.60
- IONS $52.34
- Technical
- Relative Strength Index (RSI)
- DORM 35.74
- IONS 44.54
- Support Level
- DORM $109.73
- IONS $27.57
- Resistance Level
- DORM $114.62
- IONS $29.04
- Average True Range (ATR)
- DORM 5.17
- IONS 1.79
- MACD
- DORM -0.56
- IONS 0.12
- Stochastic Oscillator
- DORM 10.96
- IONS 68.15
About DORM Dorman Products Inc.
Dorman Products Inc is a supplier of original equipment parts for automobiles. The company produces automotive and heavy-duty replacement parts, automotive hardware, brake parts, and fasteners for the automotive and heavy-duty aftermarket. The products are sold under the Dorman brand and its sub-brands OE Solutions, Help!, Conduct-Tite, and HD Solutions through aftermarket retailers, regional and local warehouse distributors, specialty markets, and salvage yards. It operates as a single reportable operating segment, namely, the sale of replacement and upgrades parts in the motor vehicle aftermarket industry, serving passenger cars, light-, medium-, and heavy-duty trucks as well as specialty vehicles. The company operates in the United States.
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.